Rodino-Klapac Louise, Head of R&D and Chief Scientific Officer at Sarepta Therapeutics (SRPT), has demonstrated a consistent pattern of selling activity over the past two years, with no recorded purchases. SEC filings reveal 32 transactions totaling $2.52 million in sales, all concentrated in SRPT shares. The most significant disposals occurred in early 2025, including a $828,563 transaction on March 7 and a $359,244 sale on June 24, 2024. Activity intensified in March 2025, with seven sales in the first ten days of the month alone, amounting to over $1.5 million in aggregate value.
More recent filings show smaller but continued dispositions, including a $60,231 sale on March 2, 2026, followed by three additional transactions later that month ranging from $8,542 to $16,144. The absence of any buy transactions and the persistence of sales—even at reduced volumes in 2026—suggest a steady unwinding of positions. The transactions, marked with codes "F" (sale) and "A/M" (awards or option exercises), indicate that while some sales stem from vested equity, others represent outright disposals. The pattern reflects a clear directional bias toward reducing exposure to SRPT, though the pace has slowed compared to the concentrated selling in early-to-mid 2025.
AI-assisted summary